去纤维钠可以治好肝小静脉闭塞病吗？

The U.S. Food and Drug Administration (FDA) approves the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

Hepatic veno-occlusive disease is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe hepatic veno-occlusive disease can be as high as 100%. Defibrotide is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide (sodium defibrotide) is a safe and effective drug for the prevention and treatment of hepatic veno-occlusive disease after HSCT.

Defibrotide (defibrotide sodium) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, Richardson et al. first explored its application in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d). The results showed that 42% of the patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and the patients could tolerate defibrotide (defibrotide sodium) well. Since then, a number of clinical trials have confirmed the effectiveness of defibrotide (defibrotide sodium) in the treatment of HVOD.

The recommended dose of defibrotide (Defibrotide Sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Administer defibrotide (sodium defibrotide) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Defibrotide (Defibrotide Sodium) must be diluted before infusion.

Prior to administration of defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Defibrotide (Defibrotide Sodium) was administered by constant intravenous infusion over a 2-hour period. Administer the dilute (defibrinated sodium) solution using an infusion set equipped with a 0.2 μm in-line filter. Flush the intravenous administration line (peripheral or central) with 5% dextrose injection, USP, or 0.9% sodium chloride injection, USP, before and immediately after administration.

Recommended related hot articles: /newsDetail/83359.html